Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products, Advance Intermediates, Fine Ingredients, Crop Science Ingredients, Life Science Chemicals and Nutritional Products.
It also provides services in Contract Manufacturing of Sterile Injectable and Drug Discovery Solutions.
Over the years, Jubilant Life Sciences has extended its footprint beyond India in the USA, Canada, Europe, and other countries across the globe. The company has a network of 7 world class manufacturing facilities in India and 5 in North America and a team of around 6100 multicultural people across the globe with ~ 1200 in North America and ~900 in R&D.
Deutsche Securities which held 3,103,408 shares or 1.95% exited the company with complete stake sale to Citigroup Global Markets.
Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion.